ArticleHepatology (Baltimore, Md.)2019
MERIT: Systematic Analysis and Characterization of Mutational Effect on RNA Interactome Topology.
Article in Hepatology (Baltimore, Md.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Integrated Bioinformatics Analysis of Differentially Expressed RNA-Binding Proteins in Human Gliomas.Cellular and molecular neurobiology · 2025Article
- Single-cell RNA binding protein regulatory network analyses reveal oncogenic HNRNPK-MYC signalling pathway in cancer.Communications biology · 2023Article
- Long noncoding RNA LINC01132 enhances immunosuppression and therapy resistance via NRF1/DPP4 axis in hepatocellular carcinoma.Journal of experimental & clinical cancer research : CR · 2022Article
- Robust prognostic model based on immune infiltration-related genes and clinical information in ovarian cancer.Journal of cellular and molecular medicine · 2022Article
- Global RNA editing identification and characterization during human pluripotent-to-cardiomyocyte differentiation.Molecular therapy. Nucleic acids · 2021Article
- ImmReg: the regulon atlas of immune-related pathways across cancer types.Nucleic acids research · 2021Article
- Molecular biomarkers in early stage lung cancer.Translational lung cancer research · 2021Review
- e-MutPath: computational modeling reveals the functional landscape of genetic mutations rewiring interactome networks.Nucleic acids research · 2021Article
- Article
- Systematic analysis of enhancer regulatory circuit perturbation driven by copy number variations in malignant glioma.Theranostics · 2021Article
- Editorial: Perturbation of RNA Binding Protein Regulation in Cancer.Frontiers in genetics · 2021Article
- Development and Validation of a Prognostic Model of RNA-Binding Proteins in Colon Adenocarcinoma: A Study Based on TCGA and GEO Databases.Cancer management and research · 2021Article
- RBP EIF2S2 Promotes Tumorigenesis and Progression by Regulating MYC-Mediated Inhibition via FHIT-Related Enhancers.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Complex impact of DNA methylation on transcriptional dysregulation across 22 human cancer types.Nucleic acids research · 2020Article
- Dynamic Expression of mFrontiers in cell and developmental biology · 2020Article
- Integrated Analysis of the Functions and Prognostic Values of RNA Binding Proteins in Lung Squamous Cell Carcinoma.Frontiers in genetics · 2020Article
- Molecular Characterization and Clinical Relevance of RNA Binding Proteins in Colorectal Cancer.Frontiers in genetics · 2020Article
- Gain-of-Function Mutations: An Emerging Advantage for Cancer Biology.Trends in biochemical sciences · 2019Review
- The role of the protein-RNA recognition code in neurodegeneration.Cellular and molecular life sciences : CMLS · 2019Review
- Systematically Dissecting the Function of RNA-Binding Proteins During Glioma Progression.Frontiers in genetics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 3 countries.
Funding
Abstract
The interaction between RNA-binding proteins (RBPs) and RNA plays an important role in regulating cellular function. However, decoding genome-wide protein-RNA regulatory networks as well as how cancer-related mutations impair RNA regulatory activities in hepatocellular carcinoma (HCC) remains mostly undetermined. We explored the genetic alteration patterns of RBPs and found that deleterious mutations are likely to occur on the surface of RBPs. We then constructed protein-RNA interactome networks by integration of target binding screens and expression profiles. Network analysis highlights regulatory principles among interacting RBPs. In addition, somatic mutations selectively target functionally important genes (cancer genes, core fitness genes, or conserved genes) and perturb the RBP-gene regulatory networks in cancer. These regulatory patterns were further validated using independent data. A computational method (Mutational Effect on RNA Interactome Topology) and a web-based, user-friendly resource were further proposed to analyze the RBP-gene regulatory networks across cancer types. Pan-cancer analysis also suggests that cancer cells selectively target "vulnerability" genes to perturb protein-RNA interactome that is involved in cancer hallmark-related functions. Specifically, we experimentally validated four pairs of RBP-gene interactions perturbed by mutations in HCC, which play critical roles in cell proliferation. Based on the expression of perturbed RBP and target genes, we identified three subtypes of HCC with different survival rates. Conclusion: Our results provide a valuable resource for characterizing somatic mutation-perturbed protein-RNA regulatory networks in HCC, yielding valuable insights into the genotype-phenotype relationships underlying human cancer, and potential biomarkers for precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.